Dr. Miranda is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-745-2535
Education & Training
Vanderbilt University Medical CenterFellowship, Hematopathology, 1995 - 1998
Brown UniversityResidency, Pathology-Anatomic and Clinical, 1991 - 1995
Cayetano Heredia UniversityClass of 1983
Certifications & Licensure
TX State Medical License 2007 - 2025
PA State Medical License 1995 - 2004
FL State Medical License 1978 - 1981- American Board of Pathology Anatomic Pathology & Clinical Pathology
- American Board of Pathology Hematology
Publications & Presentations
PubMed
- 15 citationsrearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma.Lianqun Qiu, Guilin Tang, Shaoying Li, Francisco Vega, Pei Lin
Haematologica. 2023-06-01 - 1298 citationsThe 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos, Ayoma D Attygalle, Iguaracyra Barreto de Oliveira Araujo
Leukemia. 2022-07-01 - 16 citationsCyclin D1 expression in Rosai-Dorfman disease: a near-constant finding that is not invariably associated with mitogen-activated protein kinase/extracellular signal-reg...Sofia Garces, L Jeffrey Medeiros, Mario Luiz Marques-Piubelli, Sheila Aparecida Coelho Siqueira, Roberto N Miranda
Human Pathology. 2022-03-01
Journal Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma: A ReviewL Jeffrey Medeiros, Mark W Clemens, Roberto N Miranda, Nature
Abstracts/Posters
- MYC Expression in Systemic Anaplastic Large Cell Lymphoma: Clinicopathologic and Prognostic Features of 70 PatientsRoberto N. Miranda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or...Roberto N. Miranda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
Roberto N. Miranda, MD, a Pathologist and Hematopathologist in TexasOctober 18th, 2019
Breast Implant-Associated Lymphoma on the RiseApril 11th, 2019
Miranda RN, Clemens MW (2018) Letter to the Editor Regarding: Fleming D, Stone J, Tansley P. Spontaneous Regression and Resolution of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Implications for Research, Diagnosis and Clinical Management...June 11th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
